Calluna Pharma Completes Dosing in Phase 2 AURORA Study of CAL101 in Idiopathic Pulmonary Fibrosis and Reports Completion of Final Independent Safety Review
For best results when printing this announcement, please click on link below: Calluna Pharma Completes Dosing in Phase 2 AURORA Study of CAL101 in Idiopathic Pulmonary Fibrosis and Reports Completion of Final Independent Safety Review Final independent safety review identifies no findings warranting study changes and r